Abstract
N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stages 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a starting point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyltransferases / antagonists & inhibitors*
-
Acyltransferases / metabolism
-
Aminopyridines / chemical synthesis
-
Aminopyridines / chemistry*
-
Aminopyridines / pharmacokinetics
-
Aminopyridines / pharmacology*
-
Animals
-
Brain / metabolism
-
Crystallography, X-Ray
-
Drug Design
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology
-
Humans
-
Mice
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry*
-
Sulfonamides / pharmacokinetics
-
Sulfonamides / pharmacology*
-
Trypanocidal Agents / chemical synthesis
-
Trypanocidal Agents / chemistry*
-
Trypanocidal Agents / pharmacokinetics
-
Trypanocidal Agents / pharmacology*
-
Trypanosoma brucei brucei / drug effects*
-
Trypanosoma brucei brucei / enzymology*
-
Trypanosomiasis, African / drug therapy*
-
Trypanosomiasis, African / metabolism
Substances
-
Aminopyridines
-
DDD 85646
-
Enzyme Inhibitors
-
Sulfonamides
-
Trypanocidal Agents
-
Acyltransferases
-
glycylpeptide N-tetradecanoyltransferase